Table 19.8 Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival	(Domaont)								
Year of Diagnosis:	(Percent)								
1960-1963 ^a	_	_	_	31	31	31	_	_	_
1970-1903 1970-1973 ^a		_		41	39	43		_	_
1975–1973 1975–1977 ^b	46.5	45.6	47.5	46.8	46.3	47.3	48.6	42.6	55.3 ^g
1975-1977 1978-1980 ^b	47.9	46.1	49.8	47.9	46.2	49.5	51.1	46.9	56.7
1978-1980 1981-1983 ^b	50.6	50.3	50.9	50.8	50.5	51.1	49.5	49.2	49.8
1981-1983 1984-1986 ^b									
1984-1986- 1987-1989 ^b	51.6	50.1	53.4	52.1	50.7	53.7	46.8	44.5	49.9
	50.9	47.6	54.9	51.3	48.2	55.2	45.7	41.3	51.0
1990-1992 ^b	50.7	46.7	55.7	51.5	47.6	56.4	42.2	38.4	47.6
1993-1995 ^b	52.6	48.7	57.5	53.3	49.8	57.7	42.5	35.9	54.9
1996-1998 ^b	58.8	57.0	61.0	59.5	57.7	61.5	54.7	53.1	57.2
1999-2001 ^b	64.0	61.4	67.0	65.0	62.8	67.6	55.8	49.0	63.8
2002-2004 ^b	69.8	68.6	71.2	71.0	70.1	72.1	63.6	61.1	66.6
2005-2008 ^b	71.6	70.6	72.7	72.8	71.9	73.8	62.5	57.8	67.5
2009-2015 ^b	74.7 [±]	73.9 ^f	75.7 ^f	75.7 ^f	74.8 ^f	76.7 ^f	69.5 ^f	67.0 ^f	72.4 ^f
5-Year Period Survival (I	Percent) ^{cd}								
2015	72.2	70.5	74.3	72.6	70.8	74.7	67.1	64.1	70.3
Stage Distribution (%) 20	109-2015 ^{ce}								
All Stages	307 2013								
Number of cases	97,737	53,606	44,131	80,120	44,109	36,011	8,184	4,388	3,796
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	27	27	29	27	26	28	28	25	31
	15	15	15	15	15	20 15	15	25 15	15
Regional	50	51		51	52		51		
Distant			48 8	7		49 8		54	48
Unstaged/Unknown	8	7	8	/	7	8	6	6	7
5-Year Relative Survival	(Percent), 2	009-2015 ^c							
Age at Diagnosis:									
Ages <45	84.0	82.0	87.0	85.5	83.6	88.5	73.5	70.8	77.6
Ages 45-54	81.0	77.7	85.9	82.6	79.5	87.2	68.7	63.9	75.0
Ages 55-64	77.0	74.2	80.9	78.1	75.4	81.8	67.8	62.0	74.9
Ages 65-74	72.5	70.6	74.7	73.1	71.1	75.5	65.6	62.3	68.2
Ages 75+	55.4	53.9	56.8	55.7	53.8	57.4	48.2	44.9	50.0
Ages <65	80.0	77.3	83.8	81.2	78.7	84.9	70.1	65.9	75.9
Ages 65+	63.8	62.7	64.9	64.1	62.8	65.5	58.4	56.2	59.8
Stage ^e :									
All Stages	72.0	70.7	73.7	72.4	71.1	74.0	66.5	63.7	69.8
Localized	84.0	83.0	85.0	84.3	83.3	85.2	81.0	76.6	85.0
Regional	75.0	75.1	74.9	75.5	75.6	75.5	68.9	69.8	67.8
Distant	64.8	63.3	66.8	65.7	64.2	67.7	58.0	55.7	61.0
Unstaged/Unknown	70.3	68.6	72.3	67.9	66.2	69.8	65.9	64.8	66.6
Based on End Results dat								01.0	00.0

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2016. Expected survival rates are derived from the U.S. Annual Life Tables.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey,
Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and
Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race

developed by the SEER program. Based on follow-up of patients into 2016.

Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),

^{(2009-2011: 1-2} year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival). Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2009-2015 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.